The Congressional Budget Office on Thursday (Aug. 26) updated its model for estimating how bills that affect drug industry revenue impact drug innovation, and the new model projects a slightly smaller impact on new drug development than CBO’s past “score” of House Democrats’ Medicare drug price negotiation bill. However, the refined CBO model is not that much different from CBO’s 2019 score, and sources said it probably doesn’t change the political dynamics of the debate over Medicare drug price negotiation...